The UK and US have reached a significant commercial pact that will preserve no import taxes on UK pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to increase expenditure on pharmaceuticals through the public health system. This pledge secures that import taxes on these vital exports will stay at nothing for a period of 36 months.
This agreement follows previous statements to dramatically increase duties on patented drug products, with potential rates discussed as high as double the cost.
"This deal between the United Kingdom bolsters the global environment for innovative medicines and introduces long-overdue fairness to U.S.–U.K. drug exports," a release declared.
Commercial Importance
Pharmaceuticals constitute one of the Britain's biggest export categories to the United States, which is by far the biggest destination for leading UK drugmakers.
Trade data indicate that in the year leading up to last September, the UK sold drugs totaling over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that timeframe.
"This deal secures work, stimulates funding and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The deal entails several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, refunds were more than 20%.
Industry Background
The deal takes place against a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were heightened by arguments that US consumers were charged significantly more for the identical medicines than people in the other developed nations.
In recent months, several large drug company projects in the UK have been paused or scrapped, while major expansions have been announced toward American operations.
One official stated that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
